Fasoracetam (NS-105)

Fourth-generation racetam originally synthesized by Nippon Shinyaku in the late 1980s (NS-105), failed Phase 3 in vascular dementia, then revived by NeuroFix → Aevi → Avalo → Nobias for pediatric neuropsychiatric indications. Mechanism is chronic upregulation of mGluR receptors + GABA-B receptors + cholinergic enhancement — a slow-acting glutamate-GABA rebalancer, not an acute stimulant. Only racetam in active pivotal-track development (Nobias NB-001 for 22q11.2 deletion syndrome, FDA Orphan + RPDD Dec 2024). For Dylan-archetype: OPTIONAL-ADD PRN niche — mild anxiolytic + motivation-neutral profile at 5-30 mg AM; subtle, not life-changing. Strong candidate only if mGluR-network mutation carrier or 22q11.2DS phenotype. Hard avoid: phenibut concurrent use (case report: bradycardia HR=36, GCS=3, severe GABA-B rebound withdrawal psychosis).

Fasoracetam is unusual among racetams in that its primary characterized mechanism is adaptive (chronic-dosing) receptor upregulation rather than acute receptor agonism or modulation. Three convergent effects, all documented in rat preclinical work and consistent with the limited human data:

1. mGluR upregulation (all three groups). Metabotropic glutamate receptors are G-protein-coupled (not ionotropic like AMPA/NMDA/kainate) and modulate slow glutamatergic tone rather than fast synaptic transmission. They split into:

   • Group I (mGluR1, mGluR5) — postsynaptic, Gq-coupled, generally enhance postsynaptic excitability via PLC/IP3/DAG.
   • Group II (mGluR2, mGluR3) — presynaptic, Gi/o-coupled, reduce glutamate release (autoreceptor brake).
   • Group III (mGluR4, 6, 7, 8) — presynaptic, Gi/o-coupled, similar inhibitory autoreceptor function.

   Fasoracetam appears to act as a positive modulator that upregulates surface expression and signaling of all three groups on repeated dosing, with the strongest effect on Group II/III presynaptic autoreceptors. Net effect: glutamate transmission is rebalanced toward homeostasis rather than uniformly amplified or dampened. This is mechanistically distinct from TAK-653 (acute AMPA-receptor PAM, fast ionotropic amplification) and from memantine (acute NMDA antagonist).

2. GABA-B receptor upregulation. In rat cerebral cortex, repeated fasoracetam administration upregulates GABA-B receptor density (not function via direct agonism). Functionally this resembles phenibut's chronic effect on GABA-B but without phenibut's acute agonist burst — which both helps (no acute sedation, no recreational potential) and hurts (no acute "feeling" beyond subtle anxiolytic tone). The shared upregulation pathway is also the mechanism of greatest concern for combined use with phenibut — see Side effects.

3. Cortical acetylcholine release enhancement. Fasoracetam increases ACh release in rat cerebral cortex via modulation of choline acetyltransferase activity and vesicular ACh transporter function. This is the racetam-class characteristic effect (shared with piracetam, aniracetam, pramiracetam) and is the proximate cause of the "headache on low-choline diet" pattern reported by users.

Net subjective profile (mechanistic prediction): slow-onset (days to weeks of repeated dosing) anxiolytic with subtle cognitive smoothing — "less mental noise, easier to think clearly under social/anxious load" — but no acute kick, no euphoria, no motivation enhancement. Mechanism does not predict acute stimulant or eugeroic-like effects.

Pharmacokinetics (clinical, from the Elia 2018 adolescent ADHD study):

• Half-life: 4.06–6.99 h, mean 4.82 h across single doses 50–800 mg.
• Tmax: ~1–2 h post oral dose.
• Oral bioavailability: 79–97% (animal studies; high human bioavailability extrapolated).
• Renal excretion of unchanged parent: dominant route. Little to no enterohepatic circulation, minimal hepatic metabolism. CYP-axis interactions therefore expected to be minimal.
• No dose-proportional saturation observed up to 800 mg single-dose in adolescents.
• Dosing implication: half-life of ~5 h supports BID dosing for sustained tone (which is what every clinical protocol used). Once-daily AM dosing as in the user brief produces a clean ~10-h coverage window with full washout overnight, which is reasonable for a PRN anxiolytic but does not match the chronic-upregulation mechanism if used for trial-grade efficacy.